Skip to main content
. 2014 Jan 14;9(1):e83865. doi: 10.1371/journal.pone.0083865

Figure 5. In vivo tumor efficacy studies.

Figure 5

The in vivo efficacy of the anti-Her2 ADCs was evaluated in the NCI-N87 and HCC-1954 tumor xenografts. (A) SCID mice bearing NCI-N87 tumors were treated with a single, i.v. dose of anti-Her2 ADCs. (B) SCID mice bearing HCC-1954 tumors were treated with a single, i.v. dose of anti-Her2 ADCs.